Is Biogen Stock a Buy Now?
Over the past few years, Biogen (NASDAQ: BIIB) has been engaged in a much-talked-about journey to develop an effective Alzheimer's disease (AD) medicine. On July 6, the company announced that along with its longtime partner, Japan-based Esai, it had earned traditional approval for Leqembi, a therapy that targets patients with early AD.
It's an important achievement for Biogen, but oddly enough, the market responded with a shrug. Still, Leqembi could prove instrumental in turning Biogen's fortunes around. The company's stock has been highly volatile in recent years. But is it enough to make the company's stock a buy?
Source Fool.com
Biogen Inc. Stock
€183.10
0.190%
With 51 Buy predictions and 2 Sell predictions Biogen Inc. is one of the favorites of our community.
As a result the target price of 287 € shows a very positive potential of 56.74% compared to the current price of 183.1 € for Biogen Inc..
